Digital patient education in pharma has become a core strategy for driving awareness, activation, and adherence. Leading pharmaceutical companies are using digital health platforms to deliver reliable, personalized education that helps patients understand their condition, engage in treatment decisions, and achieve better outcomes.

Patients living with chronic conditions no longer just need information. They need empowerment, tailored guidance, and ongoing support that connects clinical care with everyday life. Using psoriasis as a flagship example, this article explores how structured digital education bridges the gap between awareness and long-term adherence, and how pharma can scale this approach across therapy areas.

For pharmaceutical companies, digital patient education creates the foundation for informed decision-making. Patient activation builds on that foundation by helping patients apply what they've learned throughout their treatment journey, translating education into measurable engagement, sustained adherence, and greater real-world impact.

Why Patient Education Matters More Than Ever

Despite significant medical progress, undertreatment remains widespread across chronic conditions. Many people living with psoriasis remain unaware of the full range of treatment options available to them. Despite effective biologic and systemic therapies, patients are often misinformed, hesitant, or disengaged from long-term management.

Recent findings from Deutsches Ärzteblatt redefine psoriasis as a systemic inflammatory disease, not merely a dermatological condition. This broader "psoriatic disease" involves inflammation of the skin, arteries, bones, and joints and is frequently linked to hypertension, metabolic syndrome, and depression. Obesity, stress, and infection are major risk factors, and around one in five patients develops psoriatic arthritis.

Such complexity is why education can no longer work as a one-time intervention. Patients need accessible, ongoing, and structured learning to recognize comorbidities, understand therapy goals, and actively participate in treatment decisions.

This is why many pharma companies are combining digital education with patient activation strategies that reinforce learning through timely, behavior-based support between clinical visits.

Key Success Factors of Digital Patient Education

Across pharma, the education programs that change behavior, not just awareness, tend to share the same traits. Before looking at how these play out in psoriasis specifically, it helps to name what actually makes digital education effective:

• Accessible on an ongoing basis. A single brochure or onboarding video rarely holds up as a condition evolves. Effective education is a resource patients can return to throughout their treatment journey, not a one-time handoff at diagnosis.
• Personalized to the patient's moment. Content should reflect where a patient is: newly diagnosed, starting a new therapy, managing a flare, or reviewing long-term options, rather than treating every patient the same. On MyTherapy, this means treatment guide content delivered at the right moment in a patient's journey, not a static library.
• Clinically accurate and written in plain language. Content needs to be validated and compliant, but also usable by patients without a medical background. Trust depends on both.
• Built into routines patients already have. Education embedded in a tool patients use daily gets engaged with far more naturally than content in a standalone brochure or PDF. MyTherapy patients average 8 to 10 interactions with the app per day, giving education a recurring touchpoint rather than a single exposure.
• Two-way, not one-way. The strongest programs let patients log symptoms, track how they feel, and reflect on changes over time. That turns passive reading into active self-management, and it gives pharma a feedback loop that static content never can.
• Measurable against real behavior. Pharma needs signals beyond delivery, such as adoption, sustained use, adherence trends, ePROs, and digital biomarkers, to know whether education is actually changing behavior rather than simply being seen.

These factors are not abstract. Psoriasis is where they show up most clearly, because the disease itself demands ongoing, not one-time, education.

Psoriasis in Practice: Turning Education into Better Outcomes

Psoriasis is a useful test case for these success factors because it is a condition patients live with, and must keep learning about, for decades, not weeks. New flare triggers emerge, treatment options evolve as biologics advance, and the picture of comorbidities widens with age. A single education session at diagnosis cannot cover what a patient will need to know years later.

That is precisely what ongoing, personalized digital education is built to solve, and MyTherapy's own data shows a trend consistent with it working: mood and wellbeing tracking among psoriasis patients has increased by more than 300% since early 2023. Because mood tracking is an active behavior, requiring patients to open the app, reflect, and log how they feel, this growth suggests more than content exposure. It is a signal, not proof, that patients are increasingly connecting skin symptoms to mood, joint pain, and overall wellbeing, and coming prepared with sharper questions for their dermatologist or GP.

This is where patient activation extends education beyond information, helping patients stay engaged long after the initial learning experience.

Building a Connected Digital Education Ecosystem

For pharmaceutical companies, digital patient education creates the greatest value when it becomes part of a broader patient activation strategy.

‍Rather than delivering information as isolated campaigns, activation combines education, behavioral science, and personalized support to guide patients throughout their treatment journey, and the same foundation carries across therapeutic areas rather than needing to be rebuilt for each one.

Through MyTherapy, pharma partners can turn educational intent into measurable patient impact. This connected approach enables pharma to:

• Target with precision: Reach precisely defined patient communities, such as more than 53,000 psoriasis patients on MyTherapy, at key moments in the treatment journey.
• Educate with purpose: Transform complex medical information into accessible, evidence-based content that drives understanding and sustained adherence.
• Guide contextually: Support patients as they prepare for appointments, track symptoms, and explore treatment options.
• Measure what matters: Track outcomes through ePROs, digital biomarkers, and adherence signals, alongside AI-driven personalization, gamification, and secure caregiver and physician sharing.

The same model already shows results outside dermatology. In type 2 diabetes, adding behavioral gamification, progress visualization, achievement badges, and streak-based feedback around existing self-management features drove an 8.8 percentage point lift in active retention sustained over six months, without changing the underlying treatment pathway.

In preventive kidney health, a structured learning journey delivered inside daily app routines lifted patients' intent to seek testing by 77%. In both cases, the mechanism is the same one at work in psoriasis: education that meets patients inside behaviors they already repeat, rather than content they have to seek out separately. That means a program built for psoriasis, or diabetes, or chronic kidney disease is not a one-off.

It is a template pharma partners can adapt to their next therapy area, reaching more patients and accelerating program launches while maintaining consistent standards of compliance and quality.

See how patient activation can extend the impact of your patient education programs.

→ Talk to a Patient Activation Expert

The Takeaway: Digital Patient Education Creates Real-World Impact for Pharma

Pharma companies that integrate digital patient education into their engagement strategy can:

• Strengthen trust and long-term patient relationships.
• Improve therapy adherence and health outcomes.
• Generate real-world evidence on patient activation and engagement.

By partnering with MyTherapy, pharma can turn awareness into action, activate patients at scale, and transform education into measurable health impact.

Digital patient education creates awareness. Patient activation transforms that awareness into measurable engagement and long-term health outcomes.

See how digital education becomes measurable engagement for patients in your treatment area.

→ Book a free consultation with one of our Patient Activation experts